Introduction: The HSP90AA1 gene has been linked to a number of malignancies, but its precise function is still unknown, and no research has examined the connection between HSP90AA1 and pan-cancer. Therefore, further investigation into the relationship between HSP90AA1 and pan-cancer is required. Methods: We utilized the human protein atlas (HPA) to analyze HSP90AA1 mRNA and protein expression levels in human organs, tissues, and cell lines. Subsequently, the 33 different cancer types' levels of HSP90AA1 mRNA expression were assessed, and a range of tumor types had their diagnostic and prognostic values assessed. Additionally, the regions with the most prevalent HSP90AA1 mutation types were found. HSP90AA1's PPI and miRNA regulatory networks were established, and its activating or inhibiting effects in established pathways were examined. Finally, we looked at the connection between immune cell and regulator infiltration levels in various cancers and the expression levels of HSP90AA1. Results: The nasopharynx, testis, fallopian tube, bronchus, duodenum, gallbladder, and epididymis are the primary organs that express the HSP90AA1 protein. Thirty-three cancers have elevated HSP90AA1 mRNA expression as compared to normal tissues. The most prevalent HSP90AA1 mutation location is X585. Analysis of HSP90AA1 as a diagnostic marker in pan-cancer showed that the good diagnostic utility of HSP90AA1 in a range of cancer types. High HSP90AA1 expression groups had poorer prognosis and were associated with clinical parameters. GO/KEGG and GSEA analyses showed that HSP90AA1 was mostly associated with pathways that are linked to tumor molecules and the immune system. HSP90AA1 was associated with immune cells and regulatory factors in various cancers. Discussion: HSP90AA1 plays a role in immune microenvironment modulation in a range of tumor types and is correlated with prognosis. We hope to further validate the role of HSP90AA1 in tumors through cellular and functional assays, so as to achieve the validation of the theory, basic experiments, and clinical applications, and thus promote it as a recognized prognostic marker. And the development of corresponding targeted drugs for the HSP90AA1 locus may become a major challenging direction for future development. Conclusion: HSP90AA1 was mostly associated with pathways that are linked to tumor molecules and the immune system, and was considered a potential diagnostic, prognostic, and immunological biomarker in human cancer.
Chen et al. (Thu,) studied this question.